Back to top
more

Amicus Therapeutics (FOLD)

(Delayed Data from NSDQ)

$10.31 USD

10.31
5,689,801

+0.03 (0.29%)

Updated Jul 23, 2024 04:00 PM ET

After-Market: $10.30 -0.01 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Amicus Therapeutics (FOLD) Down 9.6% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1

by Zacks Equity Research

Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.

Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.81% and -9.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Catalyst Pharma (CPRX) Q1 Earnings?

by Zacks Equity Research

Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.

    Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Amicus Therapeutics (FOLD) Up 12.4% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018

    by Zacks Equity Research

    Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.

    What's in Store for Universal Health (UHS) Q4 Earnings?

    by Zacks Equity Research

    Universal Health's (UHS) earnings in the fourth quarter are likely to gain from higher admissions and patient days.

    What's in Store for Teladoc's (TDOC) Q4 Earnings?

    by Zacks Equity Research

    Teladoc's (TDOC) Q4 earnings might suffer high expenses, partly offset by rise in revenues.

    Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?

    by Zacks Equity Research

    Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?

    by Zacks Equity Research

    Tenet Healthcare's (THC) Q4 earnings are likely to suffer lower admissions due to divestitures.

    Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.

    Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition

    by Zacks Equity Research

    Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.

    Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -14.81% and -11.63%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

    Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 6.7%

    by Zacks Equity Research

    Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

      Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

      by Zacks Equity Research

      Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

        Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates

        by Zacks Equity Research

        Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 12.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

          Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options

          by Zacks Equity Research

          Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately.

            Amicus Therapeutics (FOLD) Surges: Stock Moves 9.2% Higher

            by Zacks Equity Research

            Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

              Should You Sell Amicus Therapeutics, Inc. (FOLD) Before Earnings?

              by Zacks Equity Research

              Amicus Therapeutics, Inc. (FOLD) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session

                by Zacks Equity Research

                Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

                  Options Traders Expect Huge Moves in Amicus Therapeutics (FOLD) Stock

                  by Zacks Equity Research

                  Amicus Therapeutics (FOLD) needs Investors to pay close attention to the stock based on moves in the options market lately.

                    Company News for July 12, 2017

                    by Zacks Equity Research

                    Companies in the News are: FOLD,SLP,ARNA,EVGN,MON

                      Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 7.3%

                      by Zacks Equity Research

                      Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise over 7% on the day.

                        Amicus Provides Regulatory Update on Fabry Disease Drug

                        by Zacks Equity Research

                        Amicus Therapeutics, Inc. (FOLD) issued an update on the regulatory pathway for migalastat for the treatment of Fabry disease in the U.S.